The common effect through all these breakpoint variants is the formation of an oncogenic BRAF–KIAA1549 fusion incorporating the BRAF kinase domain, but lacking the amino-localized autoinhibitory ...

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...